These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 26082127)

  • 21. Recombinant bispecific antibodies for cancer therapy.
    Kontermann RE
    Acta Pharmacol Sin; 2005 Jan; 26(1):1-9. PubMed ID: 15659107
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transient expression of human antibodies in mammalian cells.
    Vazquez-Lombardi R; Nevoltris D; Luthra A; Schofield P; Zimmermann C; Christ D
    Nat Protoc; 2018 Jan; 13(1):99-117. PubMed ID: 29240734
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Engineered protein scaffolds as next-generation antibody therapeutics.
    Gebauer M; Skerra A
    Curr Opin Chem Biol; 2009 Jun; 13(3):245-55. PubMed ID: 19501012
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Humanization and simultaneous optimization of monoclonal antibody.
    Kuramochi T; Igawa T; Tsunoda H; Hattori K
    Methods Mol Biol; 2014; 1060():123-37. PubMed ID: 24037839
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A general approach to antibody thermostabilization.
    McConnell AD; Zhang X; Macomber JL; Chau B; Sheffer JC; Rahmanian S; Hare E; Spasojevic V; Horlick RA; King DJ; Bowers PM
    MAbs; 2014; 6(5):1274-82. PubMed ID: 25517312
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fc engineering: design, expression, and functional characterization of antibody variants with improved effector function.
    Derer S; Kellner C; Berger S; Valerius T; Peipp M
    Methods Mol Biol; 2012; 907():519-36. PubMed ID: 22907372
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
    Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
    MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Engineering antibodies for therapy.
    Adair JR
    Immunol Rev; 1992 Dec; 130():5-40. PubMed ID: 1286872
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Toward aggregation-resistant antibodies by design.
    Lee CC; Perchiacca JM; Tessier PM
    Trends Biotechnol; 2013 Nov; 31(11):612-20. PubMed ID: 23932102
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Method for generation of human hyperdiversified antibody fragment library.
    Mondon P; Souyris N; Douchy L; Crozet F; Bouayadi K; Kharrat H
    Biotechnol J; 2007 Jan; 2(1):76-82. PubMed ID: 17225253
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FX knockout CHO hosts can express desired ratios of fucosylated or afucosylated antibodies with high titers and comparable product quality.
    Louie S; Haley B; Marshall B; Heidersbach A; Yim M; Brozynski M; Tang D; Lam C; Petryniak B; Shaw D; Shim J; Miller A; Lowe JB; Snedecor B; Misaghi S
    Biotechnol Bioeng; 2017 Mar; 114(3):632-644. PubMed ID: 27666939
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Highly Evolvable Antibody Fc Domain.
    Park HI; Yoon HW; Jung ST
    Trends Biotechnol; 2016 Nov; 34(11):895-908. PubMed ID: 27173171
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Engineering antibodies for biosensor technologies.
    Goodchild S; Love T; Hopkins N; Mayers C
    Adv Appl Microbiol; 2006; 58():185-226. PubMed ID: 16509447
    [No Abstract]   [Full Text] [Related]  

  • 34. Engineering aggregation-resistant antibodies.
    Perchiacca JM; Tessier PM
    Annu Rev Chem Biomol Eng; 2012; 3():263-86. PubMed ID: 22468604
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Obtention and engineering of non-human primate (NHP) antibodies for therapeutics.
    Pelat T; Hust M; Thullier P
    Mini Rev Med Chem; 2009 Dec; 9(14):1633-8. PubMed ID: 20105119
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy.
    Almagro JC; Daniels-Wells TR; Perez-Tapia SM; Penichet ML
    Front Immunol; 2017; 8():1751. PubMed ID: 29379493
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic Antibody Engineering and Selection Strategies.
    Ministro J; Manuel AM; Goncalves J
    Adv Biochem Eng Biotechnol; 2020; 171():55-86. PubMed ID: 31776591
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular engineering and design of therapeutic antibodies.
    Presta LG
    Curr Opin Immunol; 2008 Aug; 20(4):460-70. PubMed ID: 18656541
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antibody therapeutics, antibody engineering, and the merits of protein stability.
    Demarest SJ; Glaser SM
    Curr Opin Drug Discov Devel; 2008 Sep; 11(5):675-87. PubMed ID: 18729019
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Engineering of stable bispecific antibodies targeting IL-17A and IL-23.
    Mabry R; Lewis KE; Moore M; McKernan PA; Bukowski TR; Bontadelli K; Brender T; Okada S; Lum K; West J; Kuijper JL; Ardourel D; Franke S; Lockwood L; Vu T; Frank A; Appleby MW; Wolf A; Reardon B; Hamacher NB; Stevens B; Lewis P; Lewis KB; Gilbertson DG; Lantry M; Julien SH; Ostrander C; Chan C; Byrnes-Blake K; Brody J; Presnell S; Meengs B; Levin SD; Snavely M
    Protein Eng Des Sel; 2010 Mar; 23(3):115-27. PubMed ID: 20022918
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.